Literature DB >> 21732357

Inhibitory regulation of osteoclast differentiation by interleukin-3 via regulation of c-Fos and Id protein expression.

Jaemin Oh1, Myeung Su Lee, Jeong-Tae Yeon, Sik-Won Choi, Hun Soo Kim, Hyeok Shim, Sam Youn Lee, Byung Soo Youn, Yoshifumi Yokota, Jung Ha Kim, Han Bok Kwak.   

Abstract

Interleukin-3 (IL-3) is produced under various pathological conditions and is thought to be involved in the pathogenesis of inflammatory diseases; however, its function in bone homeostasis under normal conditions or nature of the downstream molecular targets remains unknown. Here we examined the effect of IL-3 on osteoclast differentiation from mouse and human bone marrow-derived macrophages (BMMs). Although IL-3 can induce osteoclast differentiation of multiple myeloma bone marrow cells, IL-3 greatly inhibited osteoclast differentiation of human BMMs isolated from healthy donors. These inhibitory effects of IL-3 were only observed at early time points (days 0 and 1). IL-3 inhibited the expression of c-Fos and NFATc1 in BMMs treated with RANKL. However, IL-3-mediated inhibition of osteoclast differentiation was not completely reversed by ectopic expression of c-Fos or NFATc1. Importantly, IL-3 induced inhibitor of DNA binding/differentiation (Id)1 in hBMMs, while Id2 were sustained during osteoclast differentiation of mBMMs treated with IL-3. Ectopic expression of NFATc1 in Id2-deficient BMMs completely reversed the inhibitory effect of IL-3 on osteoclast differentiation. Furthermore, inflammation-induced bone erosion was markedly inhibited by IL-3 administration. Taken together, our results suggest that IL-3 plays an inhibitory role in osteoclast differentiation by regulating c-Fos and Ids, and also exerts anti-bone erosion effects.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21732357     DOI: 10.1002/jcp.22913

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Interleukin-3 plays dual roles in osteoclastogenesis by promoting the development of osteoclast progenitors but inhibiting the osteoclastogenic process.

Authors:  Huixian Hong; Zhenqi Shi; Ping Qiao; Hui Li; Erin M McCoy; Ping Mao; Hui Xu; Xu Feng; Shunqing Wang
Journal:  Biochem Biophys Res Commun       Date:  2013-10-05       Impact factor: 3.575

2.  P2X7 Receptor Function in Bone-Related Cancer.

Authors:  Elena Adinolfi; Francesca Amoroso; Anna Lisa Giuliani
Journal:  J Osteoporos       Date:  2012-08-16

3.  STAT5 is a key transcription factor for IL-3-mediated inhibition of RANKL-induced osteoclastogenesis.

Authors:  Jongwon Lee; Semun Seong; Jung Ha Kim; Kabsun Kim; Inyoung Kim; Byung-Chul Jeong; Kwang-Il Nam; Kyung Keun Kim; Lothar Hennighausen; Nacksung Kim
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

Review 4.  The Id-protein family in developmental and cancer-associated pathways.

Authors:  Cornelia Roschger; Chiara Cabrele
Journal:  Cell Commun Signal       Date:  2017-01-25       Impact factor: 5.712

5.  Water extract of the fruits of Alpinia oxyphylla inhibits osteoclast differentiation and bone loss.

Authors:  Hyunil Ha; Ki-Shuk Shim; Taesoo Kim; Chung-Jo Lee; Ji Hyung Park; Han Sung Kim; Jin Yeul Ma
Journal:  BMC Complement Altern Med       Date:  2014-09-23       Impact factor: 3.659

6.  Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase.

Authors:  Tsuyoshi Sato; Yuichiro Enoki; Yasushi Sakamoto; Kazuhiro Yokota; Masahiko Okubo; Masahito Matsumoto; Naoki Hayashi; Michihiko Usui; Shoichiro Kokabu; Toshihide Mimura; Yoshihiko Nakazato; Nobuo Araki; Toru Fukuda; Yasushi Okazaki; Tatsuo Suda; Shu Takeda; Tetsuya Yoda
Journal:  Heliyon       Date:  2015-09-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.